Pomc (141-162) [6399]
Pomc (141-162)
| SMILES | CC(C)CC(NC(=O)C1CCCN1C(=O)C(Cc1ccccc1)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CO)NC(=O)C(CCC(=O)O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(NC(=O)C(CC(N)=O)NC(=O)C1CCCN1C(=O)C(Cc1ccc(O)cc1)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(N)CCCN=C(N)N)C(C)C)C(C)C)C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(Cc1ccccc1)C(=O)O |
| InChIKey | JKMUANZFHYBAQT-UHFFFAOYSA-N |
| Sequence | RRPVKVYPNVAENESAEAFPLEF |
| HELM | PEPTIDE1{R.R.P.V.K.V.Y.P.N.V.A.E.N.E.S.A.E.A.F.P.L.E.F}$$$$ |
Chemical Properties
| Hydrogen bond acceptors | None |
| Hydrogen bond donors | None |
| Rotatable bonds | None |
| Log P | None |
| Molecular weight (Da) | None |
Database connections
|
|
No bioactivity data available.
Pomc (141-162)
Drug properties
| Molecular type | Peptide |
| Physiological/Surrogate | Surrogate |
| Approved drug | No |
Distribution across phases (no. indications)
Phase I
0
Phase II
0
Phase III
0
Phase IV
0
Database connections
|
|